骨髓增生性疾病藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物類型、給藥途徑、配銷通路、地區和競爭格局分類，2020-2030年預測

全球骨髓增生性疾病藥物市場規模預計將從2024年的99.4億美元成長至2030年的140.6億美元，複合年成長率（CAGR）為5.95%。骨髓增生性疾病（MPD）藥物是專門用於治療一組由骨髓幹細胞異常增生引起的慢性血液系統惡性腫瘤的藥物，這些腫瘤會導致血球過度生成。市場擴張的主要驅動力是全球MPD盛行率的不斷上升，而人口老化是導致盛行率上升的重要因素。此外，分子診斷技術的進步也使得疾病的早期和精準識別成為可能。

主要市場促進因素

全球骨髓增生性疾病藥物市場主要受兩大促進因素影響：骨髓增生性疾病盛行率的不斷上升以及新型療法研發的持續進步。發病率的上升和需要持續治療的患者群體不斷擴大，大大促進了市場擴張。

主要市場挑戰

全球骨髓增生性疾病藥物市場擴張的一大挑戰是先進療法的高昂費用。這一經濟障礙直接限制了患者獲得關鍵治療的機會，尤其是在醫療資源匱乏的地區，從而限制了市場的整體成長潛力。

主要市場趨勢

在全球骨髓增生性疾病藥物市場中，對標靶療法的日益關注是一個顯著趨勢，這主要得益於精準醫療的發展趨勢。這種療法研發的藥物能夠選擇性地干擾對癌細胞生長和存活至關重要的特定分子通路，從而與傳統療法相比，提供更高的療效和更佳的安全性。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球骨髓增生性疾病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（原發性骨髓纖維化、真性紅血球增多症增多症、原發性血小板增多症、嗜酸性粒細胞增多症、系統性肥大細胞增多症）
  • 依藥物類型（JAK2抑制劑、抗腫瘤藥、去甲基化劑、甲磺酸伊馬替尼、其他）
  • 依給藥途徑（口服、父母給藥、其他）
  • 依配銷通路（醫院藥局、零售店、藥局）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美骨髓增生性疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲骨髓增生性疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區骨髓增生性疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲骨髓增生性疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲骨髓增生性疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球骨髓增生性疾病藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• AbbVie, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc

第16章：策略建議

第17章調查會社について,免責事項

The Global Myeloproliferative Disorders Drugs Market will grow from USD 9.94 Billion in 2024 to USD 14.06 Billion by 2030 at a 5.95% CAGR. Myeloproliferative Disorders (MPDs) drugs comprise a specialized pharmaceutical segment focused on treating a group of chronic hematological malignancies stemming from aberrant bone marrow stem cell proliferation, leading to an overproduction of blood cells. The market's expansion is primarily propelled by the increasing global prevalence of MPDs, which is significantly influenced by an aging demographic, alongside advancements in molecular diagnostics that enable earlier and more precise disease identification.

Key Market Drivers

The Global Myeloproliferative Disorders Drugs Market is significantly influenced by two primary drivers: the increasing prevalence of myeloproliferative disorders and continuous advancements in the research and development of novel therapies. The rising incidence and growing patient populations requiring ongoing management contribute substantially to market expansion.

Key Market Challenges

A notable challenge impeding the expansion of the Global Myeloproliferative Disorders Drugs Market is the substantial cost associated with advanced therapies. This financial barrier directly limits patient access to critical treatments, particularly within underserved regions, thereby restricting the overall growth potential of the market. High treatment expenses create a significant economic burden for patients and healthcare systems alike, often resulting in delayed or foregone treatment initiation and compromised adherence.

Key Market Trends

The increasing focus on targeted therapies represents a significant trend in the Global Myeloproliferative Disorders Drugs Market, driven by the shift towards precision medicine. This approach develops drugs that selectively interfere with specific molecular pathways crucial for the growth and survival of cancer cells, thereby offering enhanced efficacy and a more favorable safety profile compared to conventional treatments.

Key Market Players

• AbbVie, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Myeloproliferative Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myeloproliferative Disorders Drugs Market, By Type:

• Primary Myelofibrosis
• Polycythemia Vera
• Essential Thrombocythemia
• Hyper eosinophilic Syndrome
• Systemic Masto cytosis

Myeloproliferative Disorders Drugs Market, By Drug Type:

• JAK2 Inhibitors
• Anti-Neoplastics
• Demethylation Agents
• Imatinib Mesylate
• Others

Myeloproliferative Disorders Drugs Market, By Route of Administration:

• Oral
• Parental
• Others

Myeloproliferative Disorders Drugs Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Stores
• Drug Stores

Myeloproliferative Disorders Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Myeloproliferative Disorders Drugs Market.

Available Customizations:

Global Myeloproliferative Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myeloproliferative Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Hyper eosinophilic Syndrome, Systemic Masto cytosis)
  • 5.2.2. By Drug Type (JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Others)
  • 5.2.3. By Route of Administration (Oral, Parental, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Stores, Drug Stores)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Myeloproliferative Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Myeloproliferative Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Myeloproliferative Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Myeloproliferative Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Myeloproliferative Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Myeloproliferative Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Novartis AG
• 15.4. AstraZeneca PLC
• 15.5. Johnson and Johnson Services, Inc.
• 15.6. Sun Pharmaceutical Industries Ltd.
• 15.7. Hikma Pharmaceuticals PLC
• 15.8. Teva Pharmaceutical Industries Ltd.
• 15.9. Pfizer Inc.
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer